巴兹西芬作为一种潜在的癌症治疗剂,向IL-6/GP130信号传输
Changyou Shi1, Taylor Bopp1, Hui-Wen Lo2
1Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Current oncology (Toronto, Ont.)
|October 25, 2024
概括
骨质疏松症药物巴兹多克西芬 (BZA) 在癌症治疗中表现有前途,它通过抑制互白素-6 (IL-6) /糖蛋白130 (GP130) 途径来治疗癌症. 这种药物可能提供新的癌症治疗选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 介质素-6 (IL-6) /糖蛋白130 (GP130) 途径对于癌细胞的存活和进展至关重要.
- 准这种途径为癌症治疗提供了一个有希望的策略.
研究的目的:
- 审查巴兹多克西芬 (BZA) 的抗癌活性.
- 通过IL-6/GP130通路抑制,阐明BZA通过IL-6/GP130通道抑制的抗癌作用机制.
- 在瘤临床试验中探索BZA的潜在重新定位.
主要方法:
- 文献综述侧重于BZA的疗效和作用机制.
- 对调查BZA在抑制IL-6/GP130信号通路中的作用的研究分析.
- 检查BZA在各种癌症类型的治疗潜力,包括单疗法和组合治疗.
主要成果:
- 美国食品和药物管理局批准用于骨质疏松症的药物巴兹多克西芬 (BZA) 也抑制了IL-6/GP130相互作用.
- 在多种癌症类型中,BZA在阻碍癌症进展方面表现出有效性.
- 研究强调了BZA作为单一疗法或与化疗剂结合的潜力.
结论:
- 通过抑制IL-6/GP130通路,BZA具有显著的抗癌潜力.
- 需要进一步的研究和临床试验来探索BZA在癌症治疗中的重新定位.
- BZA代表了新瘤疗法的一个有前途的候选人.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


